ArchiveApril 2011

Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis.

Cohen & Chun; Ann Neurol. 2011 May;69(5):759-77. In addition to its immune effects Fingolimod readily penetrates the CNS and may have direct effects on neural cells. This central mechanism of action distinguishes Fingolimod from other immunosuppressive drugs and may explain its positive effects on reducing the rate of brain atrophy. “Whether Fingolimod is neuroprotective is not a moot...

AAN IN11-2.005 Identification of Epstein-Barr Virus Associated Epigenetic Changes and Association with Multiple Sclerosis

Ramagopalan, et al. OBJECTIVE: To investigate whether EBV associated changes to the epigenome are involved in the pathogenesis of MS. BACKGROUND: The epigenome are the chemical changes that happen to the DNA that do not affect the actual coding sequence of the DNA, but rather how the cell reads and processes the information coded in the sequence. As you may know already symptomatic EBV infection...

AAN P05.065: Remote EBV Seropositivity at First Attack in Children Increases MS Risk Independent of Other Common Childhood Viruses

Makhani, et al. AIMS: This study analysed Epstein-Barr virus (EBV), cytomegalovirus (CMV), varicella-zoster virus (VZV), and herpes simplex virus (HSV) in children with a first attack of central nervous system demyelination (ADS). RESULTS: Children diagnosed with MS were more likely than those with monophasic ADS, i.e. non-MS, to be seropositive for remote EBV infection (37/49 vs 82/185, p

Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients

Garcia-Montojo et al. Eur J Neurol. 2011 Apr 25. Human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) are associated with MS. Once infected with these viruses you remain infected with them for life. These viruses have a latent or dormant phase, were they hibernate within the body, and an active or lytic phase characterised by viral replication. IFN-beta may work via its antiviral properties...

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

Krupp et al. Neurology. 2011 Apr 26;76(17):1500-7. The aim of this study was to determine if memory could be improved by donepezil, the drug licensed for memory impairment in Alzheimer’s disease, in PwMS. Unfortunately, Donepezil did not improve memory as compared to placebo. “Memory impairment in MS is one of the hidden disabilities and clearly a difficult one to treat. A further...

Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low

Wong et al. Can J Neurol Sci. 2011 May;38(3):429-33. Patient adherence to various disease-modifying drugs (DMDs) in the treatment of MS is a major problem. Cumulative persistence rates for all four injectable DMDs were similar over time and ranged from 73.6-79.1% at six months, 59.1-63.1% at one year and 41.5-47.4% at two years. Adherence to DMDs in adult MS patients is poor, which is consistent...

Suicide attempts in multiple sclerosis

Stenager, et al. Mult Scler. 2011 Apr 20. Aims: (1) to estimate the risk of suicide attempts in PwMS in Denmark and compare the risk to the background population; (2) to estimate the risk of suicide attempts in PwMS receiving immunomodulating therapy compared with untreated patients. Results: No increased risk for suicide attempts was found in PwMS. No difference in number of suicide attempts in...

FDA details timeframe of MS drug Tysabri’s risks

The potentially fatal infection, known as progressive multiform leukoencephalopathy (PML), occurs in an estimated 1.5 per 1,000 patients treated with Tysabri during months 25 to 36. The PML risk was 0.3 per 1,000 patients during the first two years of treatment. After three years, the rate was 0.9 per 1,000. Limited data is available beyond four years. For the first time the FDA said it had...

Translate

Categories

Recent Posts

Recent Comments

Archives